Department of Obstetrics and Gynecology, Faculty of Medical and Health Sciences, The Yitzhak Shamir Medical Center (Formerly Assaf Harofeh Medical Center), affiliated with the School of Medicine, Tel Aviv University, Zerifin, Tel Aviv, Israel.
Arch Gynecol Obstet. 2024 Sep;310(3):1607-1610. doi: 10.1007/s00404-024-07625-9. Epub 2024 Jul 16.
Advances in ultrasound and molecular genetics have changed the field of late termination of pregnancy (LTOP), sparking ethical debates worldwide. In 2007, Israel updated its LTOP policies, requiring a 30% or higher probability of severe handicap for approval of LTOP after 24 weeks' gestation.
In this retrospective study, we compared LTOP indications and approval rates before (Group 1: 1998-2007) and after (Group 2: 2008-2021) this policy change.
Shamir medical records from January 1, 1998 to December 31, 2021 were examined and yielded 4047 abortions, of which 248 were identified as LTOP preformed after 24 weeks' gestation. These cases were then categorized into two groups. Data including maternal age, obstetric history, indications for abortion, diagnosis, week of termination, and genetic/sonographic findings were analyzed. The approval rates and indications pre- and post-policy change were compared.
Group 1 (LTOP 1998-2007) comprised 95 cases (10.6%), and Group 2 (LTOP 2008-2021) was composed of 153 cases (4.9%). Fetal structural anomalies remained the dominant indication for both groups (67.4 and 65.3%, respectively), with a slight increase in confirmed genetic anomalies from 26.3% (Group 1) to 28% (Group 2).
Our findings indicate a decrees in the proportion per year from 10.6 to 4.9% LTOP. Technological advances in genetic evaluation and sonography may have contributed to the early increased detection and decrees in cases reaching LTOP. These results highlight the importance of ongoing ethical reviews and adherence to strict protocols for early detection and termination before 24 weeks' gestation.
超声和分子遗传学的进步改变了终止晚期妊娠(LTOP)领域,引发了全球范围内的伦理辩论。2007 年,以色列更新了其 LTOP 政策,要求在 24 周妊娠后,严重残疾的概率达到 30%或更高才能批准 LTOP。
在这项回顾性研究中,我们比较了该政策改变前后(第 1 组:1998-2007 年;第 2 组:2008-2021 年)的 LTOP 指征和批准率。
检查了 Shamir 医疗记录,时间范围为 1998 年 1 月 1 日至 2021 年 12 月 31 日,共进行了 4047 次流产,其中 248 次被确定为 24 周妊娠后进行的 LTOP。这些病例随后分为两组。分析了包括母亲年龄、产科史、流产指征、诊断、终止周数和遗传/超声检查结果等数据。比较了政策改变前后的批准率和指征。
第 1 组(1998-2007 年的 LTOP)包括 95 例(10.6%),第 2 组(2008-2021 年的 LTOP)由 153 例组成(4.9%)。胎儿结构异常仍然是两组的主要指征(分别为 67.4%和 65.3%),确诊遗传异常的比例略有增加,从 26.3%(第 1 组)增加到 28%(第 2 组)。
我们的发现表明,LTOP 的年比例从 10.6%降至 4.9%。遗传评估和超声技术的进步可能导致早期检测率增加,到达 LTOP 的病例减少。这些结果强调了对早期检测和 24 周妊娠前终止妊娠进行持续伦理审查和遵守严格协议的重要性。